 |
|
|
| |
Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13-17, 2016
Poordad F,1 Fontana RJ,2 Schiff ER,3 Vierling JM,4 Landis C,5 Zhao Y,6 Gandhi Y,6 Garimella T,6 Eley T,6 Noviello S,6 Swenson ES7
1Texas Liver Institute, The University of Texas Health Science Center, San Antonio, TX, USA; 2University of Michigan Medical Center, Ann Arbor, MI, USA; 3Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA; 4Baylor College of Medicine, Houston, TX, USA; 5University of Washington School of Medicine, Seattle, WA, USA; 6Bristol-Myers Squibb, Princeton, NJ, USA; 7Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
